Real-time Estimate
Cboe BZX
02:24:15 2024-07-10 pm EDT
|
5-day change
|
1st Jan Change
|
0.492
USD
|
+3.34%
|
|
0.00%
|
-43.53%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
30.84
|
8.148
|
30.16
|
17.9
|
-
|
-
|
Enterprise Value (EV)
1 |
30.84
|
8.148
|
30.16
|
17.9
|
17.9
|
17.9
|
P/E ratio
|
-2.4
x
|
-0.45
x
|
-0.68
x
|
-0.44
x
|
-1.9
x
|
0.22
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
73.5%
|
Capitalization / Revenue
|
-
|
8.57
x
|
44.7
x
|
-
|
0.58
x
|
0.07
x
|
EV / Revenue
|
-
|
8.57
x
|
44.7
x
|
-
|
0.58
x
|
0.07
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-5.32
x
|
-
|
-
|
-0.37
x
|
-0.51
x
|
0.27
x
|
FCF Yield
|
-18.8%
|
-
|
-
|
-268%
|
-195%
|
369%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
14,973
|
15,089
|
34,754
|
37,607
|
-
|
-
|
Reference price
2 |
2.060
|
0.5400
|
0.8677
|
0.4761
|
0.4761
|
0.4761
|
Announcement Date
|
3/31/22
|
3/31/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
0.951
|
0.675
|
-
|
30.95
|
238.9
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-8.977
|
-18.05
|
-20.77
|
-29.26
|
-28.97
|
127
|
Operating Margin
|
-
|
-
|
-1,898.21%
|
-3,077.63%
|
-
|
-93.61%
|
53.15%
|
Earnings before Tax (EBT)
1 |
-
|
-10.02
|
-18.06
|
-30.54
|
-40.56
|
-27.95
|
141.4
|
Net income
1 |
-2.264
|
-10.02
|
-18.06
|
-31.41
|
-40.77
|
-27.95
|
105.3
|
Net margin
|
-
|
-
|
-1,898.84%
|
-4,653.48%
|
-
|
-90.34%
|
44.09%
|
EPS
2 |
-0.2580
|
-0.8600
|
-1.200
|
-1.280
|
-1.080
|
-0.2500
|
2.165
|
Free Cash Flow
1 |
-
|
-5.796
|
-
|
-
|
-48
|
-35
|
66
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-113.1%
|
27.63%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
62.66%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
0.3500
|
Announcement Date
|
2/18/21
|
3/31/22
|
3/31/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
0.951
|
-
|
0.675
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-2.752
|
-3.537
|
-3.636
|
-5.554
|
-5.325
|
-4.202
|
-4.322
|
-5.938
|
-6.313
|
-9.204
|
-7.47
|
-6.402
|
-6.186
|
-7.68
|
-6.283
|
Operating Margin
|
-
|
-
|
-
|
-584.02%
|
-
|
-622.52%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-2.752
|
-3.537
|
-3.636
|
-5.557
|
-5.328
|
-14.58
|
-3.838
|
-4.333
|
-7.798
|
-20.96
|
-6.964
|
-6.373
|
-6.285
|
-7.68
|
-6.283
|
Net income
1 |
-2.752
|
-3.537
|
-3.636
|
-5.557
|
-5.328
|
-14.77
|
-4.441
|
-4.405
|
-8.665
|
-21.17
|
-6.964
|
-6.373
|
-6.285
|
-7.68
|
-6.283
|
Net margin
|
-
|
-
|
-
|
-584.33%
|
-
|
-2,187.7%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.1700
|
-0.2400
|
-0.2400
|
-0.3700
|
-0.3500
|
-0.9700
|
-0.2900
|
-0.1300
|
-0.1600
|
-0.6100
|
-0.1950
|
-0.1825
|
-0.1775
|
-0.1867
|
-0.1867
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/31/22
|
5/12/22
|
8/15/22
|
11/14/22
|
3/31/23
|
5/16/23
|
8/14/23
|
11/14/23
|
3/28/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-5.8
|
-
|
-
|
-48
|
-35
|
66
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
0
|
-
|
12
|
8
|
2
|
Capex / Sales
|
-
|
-
|
0.21%
|
-
|
-
|
25.85%
|
0.84%
|
Announcement Date
|
2/18/21
|
3/31/22
|
3/31/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
0.4761
USD Average target price
5.75
USD Spread / Average Target +1,107.73% Consensus |
1st Jan change
|
Capi.
|
---|
| -43.53% | 17.9M | | +19.92% | 44.48B | | +44.19% | 40.57B | | -8.59% | 38.82B | | +33.77% | 32.22B | | -8.34% | 27.84B | | +15.48% | 26.79B | | +49.15% | 14.31B | | +36.04% | 12.7B | | -6.91% | 11.23B |
Other Biotechnology & Medical Research
|